Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2000-11-10
2003-04-22
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S171000
Reexamination Certificate
active
06552010
ABSTRACT:
FIELD OF THE INVENTION
The field of this invention concerns improvements in the treatment of systemic lupus erythematosus (SLE).
BACKGROUND OF THE INVENTION
REFERENCES
Alcocer-Varela, et al., J. Clin. Invest. 69:1388, (1982).
Barrett-Connor, et al. New Engl. J. Med. 315:1519, (1986).
Gutierrez-Ramos, et al., Nature 346:27, (1990).
Heinz, D., et al., Steroids Lip Res. 5(4):216 (1974).
Jungers, et al., Arthritis Rheum. 25: 454, (1982).
Krupp, L P, et al., Arch Neurol, 46:1121 (1989).
Lahita, et al., Arthritis Rheum 26:1517, (1983).
Liang, et al., Arthritis Rheum 32:1107 (1989).
Linker-Israeli, et.al., J. Immunol. 130:2651, (1983).
Lucas, et al. J. Clin. Invest. 75:2091, (1985).
Murakawy, et al., J. hmmunol 134:187, (1985).
Roubinian, et al., Arthritis Rheum. 22:1399, (1979).
Steinberg, et al., Arthritis Rheum. 22:1170, (1979).
Vande Wiele, et al. Recent Prog. Horm. Res. 19:75, (1963).
SUMMARY OF THE INVENTION
The present invention provides a method for treating systemic lupus erythematosus (SLE). The method entails administering an effective amount of a pharmaceutically active form of DHEA to an individual with SLE, and at least about 4 weeks after initiating DHEA administration, determining the following disease-activity and constitutional-symptom variables characterizing the individual's SLE condition: the SLE Disease activity index (SLEDAI), the Systemic Lupus Activity Measurement (SLAM), the Patient Visual Analog Scale (Patient VAS), and the Krupp Fatigue Severity Score (KFSS). The differences between the values for SLEDAI, KFSS, VAS, and SLAM after initiating DHEA administration and baseline values for SLEDAI, KFSS, VAS, and SLAM before initiating DHEA administration are then determined. A decrease in three of these four variables and either a decrease, no change, or an increase of no more that about 5% of a baseline value in the fourth variable indicates that the individual is responding to said DHEA administration. Preferably, the individual is a human SLE patient, and more preferably a human SLE patient with a SLEDAI value greater than 2.
The DHEA polymorphs known as forms I and II are preferred for use in the treatment method of the invention. Accordingly, in preferred embodiments, at least about 85%, and more preferably at least about 95%, of the DHEA administered is present as the form I polymorph, the form II polymorph, or a combination thereof.
In one embodiment, DHEA is administered at a dose and for a period effective to produce a decrease in three of the four disease-activity and constitutional-symptom variables characterizing an individual's SLE condition and either a decrease, no change, or an increase of no more that about 3% of a pretreatment baseline value in the fourth variable. In another embodiment, DHEA is administered at a dose effective to reduce the risk of an SLE flare at about 200 days of DHEA administration by at least about 5%. Preferably, the method entails administering a daily oral dose of at least about 100 mg, and more preferably about 200 mg, of a pharmaceutically active DHEA. In one embodiment, DHEA administration is continued for a period of at least about 40 weeks.
One advantage of the treatment method of the invention is that is can be combined with other therapies. For example, the treatment method can be carried out with an SLE patient receiving an orally administered drug, such as a glucocorticoid, a non-steroidal anti-inflammatory agent, an immunosuppressant, or an anti-malarial drug. In this case, the treatment method includes continuing administration of the drug during the period of DHEA administration.
The invention also provides a pharmaceutical product for use in treating systemic lupus erythematosus (SLE) in an individual. The pharmaceutical product includes a plurality of doses of a pharmaceutically active form of DHEA, and instructions for performing the treatment method of the invention.
The invention includes the use of the pharmaceutical product of the invention, for treating systemic lupus erythematosus (SLE) in a human patient.
Another aspect of the invention is the use of a pharmaceutically active acid, salt, or ester form dehydroepiandrosterone (DHEA) in the preparation of a tablet-form medicament for use in treating systemic lupus erythematosus (SLE) in a human patient, with a greater than 50% expectation of achieving improvement in the measured values of at least three of the disease-activity and constitutional-symptom variables characterizing a patient's SLE condition consisting of SLEDAI, KFSS, VAS, and SLAM, and an increase of no greater than 5% of a pretreatment baseline value in the fourth variable, where the change in each variable is determined from the difference between a pretreatment baseline value and values during treatment, when the patient has a pre-treatment SLEDAI value greater than 2, and is treated with a dose of at least about 100 mg per day DHEA, administered orally. In a preferred variation of this embodiment, the patient is treated with a dose of at least about 200 mg DHEA per day for a period of at least about 40 weeks.
REFERENCES:
patent: 5567696 (1996-10-01), McGuire et al.
patent: 5817650 (1998-10-01), McGuire et al.
patent: WO 94/08589 (1994-04-01), None
patent: WO 00/54763 (2000-09-01), None
“A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus”, van Vollenhoven et al., 1999, 8(3), 181-187.*
Alcocer-Varela et al.,J. Clin. Invest. 69:1388-1392 (Jun. 1982).
Barrett-Connor et al.,New Engl. J. Med. 315:1519-1524 (1986).
Bombardier et al., & The Committee on Prognosis Studies in SLE “Derivation of SLEDAI. A disease activity index for lupus patients.,”Arthritis Rheum. 35:630-640 (Jun. 1992).
Gutierrez-Ramos et al.,Nature346:271-274 (Jul. 1990).
Hawker et al., “A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus,”J. Rheumatol. 20:4:657-660 (Apr. 1993).
Heinz, D. et al.,Steroids Lip Res.5(223):216-223 (1974).
Jungers et al.,Arthritis Rheum.25:4:454-457 (Apr. 1982).
Kaki, A.M. and Lewis, G.W., “Inguinal paravascular (lumbar plexus) Neurolytic Block—Description of a Catheter Technique: case report,”Reg. Anesth. Pain. Med.23:2:214-218 (Mar.-Apr. 1998).
Krupp, L.B. et al., “The Fatigue Severity Scale: Application to Patients with Multiple Sclerosis and Systemic Lupus Erythematosus”Arch Neurol.46:1121-1123 (1989).
Lahita et al., “Increased Oxidation of Test Osterone in Systemic Lupus Erythematosus”Arthritis Rheum.26:1517 (1983).
Liang et al., “Reliability and Validity of Six Systems for the Clinical Assessment of Disease Activity in Systemic Lupus Erythematosus”Arthritis Rheum.32:9:1107-1118 (1989).
Linker-Israeli et al.,J. Immunol.130:6:2651-2655 (Jun. 1983).
Lucas et al., “Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F1Mice Fed Dehydroisoandrosterone”J. Clin. Invest.75:2091-2093 (Jun. 1985).
Morand et al., “Fibromyalgia syndrome and disease activity in systemic lupus erythematosus,”Lupus3:187-191 (Jun. 1994).
Murakawa et al., “Characterization of T Lymphocyte Subpopulations Responsible for Deficient Interleukin 2 Activity in Patients with Systemic Lupus Erythematosus”J. Immunol.134:1:187-195 (Jan. 1985).
Roubinian et al., “Danazol's Failure to Suppress Autoimmunity in NZB/NZW F1Mice”Arthritis Rheum.22:12:1399-1402 (Dec. 1979).
Shafer et al., “Preoperative anxiety and fear: a comparison of assessements by patients and anesthesia and surgery residents,”Anesth. Analg.83:1285-1291 (1996).
Sheean et al., “An open-labelled clinical and electrophysical study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis,”Brain121:967-975 (1998).
Singer et al., “Comparison of patient and practioner assessments of pain from commonly performed emergency department procedures,”Ann. Emerg. Med.33:6:652-658 (Jun. 1999).
Singer et al., “Determination of the minimal clinically significant difference on a patient visual analog satisfaction scale,”Acad. Emerg. Med.5:10:1007-1011 (Oct. 1998).
Steinberg et al., “Approach to the Study
Gurwith Marc J.
Schwartz Kenneth E.
Fay Zohreh
Genelabs Technologies, Inc.
Haliday Emily M.
Kwon Brian-Yong
Quine Intellectual Property Law Group P.C.
LandOfFree
Treatment of SLE with dehydroepiandrosterone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of SLE with dehydroepiandrosterone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of SLE with dehydroepiandrosterone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3057974